A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday.
The U.S. Food and Drug Administration approved Eli Lilly’s drug, named Zepbound. The drug, also known as tirzepatide, helped dieters lose as much as 40 to 60 pounds in testing.
Manjaro? I use that on my computer!
Oh, you said Mounjaro? Never mind.
The track record for weight loss drugs is not good. Even “approved” ones. We had a lot of teenagers on amphetamines to make them lose weight.
The podcast Maintenance Phase has at least one episode on them and their history.
The results for this and Wegovy are pretty promising. That said, the long term effects are unknown since they are so new. But the long term effects of having a BMI over 30 are pretty terrible and well known. These are nothing like amphetamines.
I’m personally a big fan of consuming fewer calories.
I’m on Wegovy and it’s a miracle, frankly.
Between the ADHD medication wreaking havoc with my hunger signals and the non-diabetic hypoglycemia causing me to go from “not hungry” to “dying of a sugar crash,” the Wegovy gave me actual satiety for the first time in my life, and evened out the crashes.
I’m a big fan of more options along these lines, for whoever they might save.
Unfortunately people gain the weight back once they stop taking the drug if there is no lifestyle change which there often is not. A guy I know owned a good chunk of Sequence which essentially fast tracked access to Wegovy through telehealth and working with insurance companies. He was pushing to partner with a company that could provide that lifestyle change info so that people could keep off the weight when they stop using it. Weight Watchers bought them so hopefully they can help provide that lifestyle change.
So far the side effects of Wegovy are fairly standard but it has only been around for 10 years and widely studied for an even shorter period since it has only been on the market for a couple years.
Ha! A grand a month. Fat chance.
